$550 | Single User
$1100 | Site License
$1650 | Global License

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others
[Published by La Merie]

Published by La Merie: 01 Nov 2016 | 31942 | In Stock
Related Topics: Protein

Introduction

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others


This Competitive Intelligence report about Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others evaluates as of November 26, 2016 the competitive field of mainly specific, but also bispecific new molecular entities inhibiting negative immune checkpoints, including



  • CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)

  • LAG-3 (Lymphocyte Activation Gene 3; CD223)

  • TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)

  • VISTA (V-region Ig-containing Suppressor of T-cell Activation) Receptor

  • CEACAM1 (Carcino-Embryonic Antigen Cell Adhesion Molecule 1)

  • BTLA (B- and T-Lymphocyte Attenuator)

  • GARP (Glycoprotein A Repetitions Predominant)

  • TIGIT (T-cell Immunoreceptor with Ig and ITIM domains)

  • IL-10 (Interleukin-10)

  • B7-H3 (CD276)


Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date as well as the clinical and preclinical combination studies. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


More than 10 antibodies inhibiting negative immune checkpoints are in clinical development as monotherapy or in combination with other checkpoint modulators or targeted cancer therapeutics. At least further five molecules are undergoing IND-enabling studies.


The report includes a compilation of currently active projects in research and development of immune checkpoint inhibitors. In addition, the report lists company-specific R&D pipelines of Immune Checkpoint Inhibitors. Competitor projects are listed in a tabular format providing information on:



  • Drug Codes,

  • Target / Mechanism of Action,

  • Class of Compound,

  • Company,

  • Product Category,

  • Indication,

  • R&D Stage and

  • additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents
for Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others [Published by La Merie]

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others

Table of Contents

1) CTLA-4 Antagonists

  • Yervoy (ipilimumab) monotherapy
  • Yervoy (ipilimumab) combination with Opdivo (nivolumab)
  • Yervoy (ipilimumab) combination with other therapeutics
  • Tremelimumab monotherapy
  • Tremelimumab combination with durvalumab
  • Tremelimumab combination with other therapeutics
  • Novel Specific CTLA-4 Antagonists
  • Novel Bispecific CTLA-4 Antagonists

2) LAG-3 Antagonists

3) TIM-3 Antagonists

4) Inhibitors of Other Negative Immune Checkpoints

5) Corporate Immune Checkpoint Inhibitor R&D Pipelines

Additional Details

Publisher

La Merie

Publisher Information

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

Reference

31942 | LMCA0158

Number of Pages

74

Report Format

PDF

La Merie Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other DiseasesThis Compet...
01 Jun 2016 by La Merie USD $560 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel a...
01 May 2016 by La Merie USD $560 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitiv...
01 May 2016 by La Merie USD $335 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 UpdateTable of Contents...
01 May 2016 by La Merie USD $335 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 UpdateThis Competitive...
01 May 2016 by La Merie USD $280 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) familyThe Compet...
17 Jan 2016 by La Merie USD $225 More Info
Physician Views: And then there were two – will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?
Scope Later this month, the FDA is expected to approve AbbVie's oral '3-DA' product - comprising Vie...
11 Dec 2014 by FirstWord Pharma USD $695 More Info
Physician Views: A Victoza competitor in waiting? – Can Eli Lilly's dulaglutide make an impact in the GLP-1 agonist market?
Scope Last week, Eli Lilly confirmed that in the head-to-head AWARD-6 study its experimental GLP-1 a...
05 Mar 2014 by FirstWord Pharma USD $695 More Info

This report is published by La Merie

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

Download Free Report Summary PDF

Competitor Analysis: Inhibitors of Negative Immune Checkpoints CTLA-4, LAG-3, TIM-3 & Others [Published by La Merie] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...